About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, November 12th, 2012

The QualityStocks
Daily Stock List


School Specialty, Inc. (SCHS)

SmarTrend Newsletters reported last week on School Specialty, Inc. (SCHS), Wall Street Resources, The Street did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Greenville, Wisconsin, School Specialty is a leading education company that lists on the NASDAQ Global Select Market. The Company provides innovative and proprietary products, programs and services to help educators engage and inspire students of all ages and abilities to learn. School Specialty serves the pre-kindergarten through 12th grade market with instructional solutions that address the wide array of educational needs - from basic school supplies to standards-based curriculum solutions. The Company offers their products and services through two operating groups: Accelerated Learning and Educational Resources. Proprietary products generate approximately half of School Specialty's revenue.

School Specialty designs, develops, and provides preK-12 educators with current and premier curriculum, supplemental learning resources, and school supplies. The Company offers their products through their sales force, catalogs, and proprietary e-commerce Websites. School Specialty works together with educators to develop the best learning solutions that are based on real-life use, classroom experiences and outcomes.

The Accelerated Learning Group provides standards-based curriculum products, supplemental curriculum materials, instructional programs and student assessment tools. Their offerings are comprehensive and targeted to address specific learning needs, drive improved student performance, engage learners and accelerate the learning process. Accelerated Learning's major products include: Wordly Wise 3000®, Premier™ Agenda, Delta Education™, FOSS®, CPO Science™, Frey Scientific®, Educator's Publishing Service, Academy of Reading®, Think Math!™, MCI®, S.P.I.R.E.® and SPARK™.

The Educational Resources Group offerings include basic school supplies, supplemental learning products, teaching resources, physical education equipment, art supplies, classroom equipment and furniture.

Educational Resources proprietary brands include: Education Essentials®, Sportime®, Childcraft®, Sax® Arts & Crafts, Califone®, abc®, Abilitations®, School Smart®, Classroom Select™ and Projects by Design®.

Recently, School Specialty announced that they scheduled their fiscal 2013 second quarter conference call for Tuesday, November 20, at 11 a.m. Eastern Time. The Company's news release detailing the quarter's financial results will be issued November 20, 2012 before the open of trading on the NASDAQ Market.

School Specialty, Inc. (SCHS), closed Monday’s session at $1.59, up 0.63%, on 76,720 volume with 352 trades. The average volume for the last 60 days is 110,636 and the stock's 52-week low/high is $1.50/$8.03.

Coastal Pacific Mining Corp. (CPMCF)

StreetInsider, PennyStockVille, PennyInvest, CoolPennyStocks, MadPennyStocks, StockEgg, BullRally, HotOTC, and StockRich reported earlier on Coastal Pacific Mining Corp. (CPMCF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Coastal Pacific Mining Corp. is an exploration stage company with corporate headquarters in Calgary, Alberta. Founded in 2007, the Company's exploration mandate is to explore, develop and mine gold and/or silver-rich resources in North and South America. Coastal Pacific Mining will partner with companies having mineral properties suitable for development and production. The Company currently has agreements in place for properties in Ontario, Canada and the Province of Huancavelica, Peru.

Coastal Pacific Mining's philosophy is to participate with Companies who are in the later stage of exploration and are ready for development. The Company's projects include The Santa Rita Property. The Property is in the District of Acobambilla, Province of Huancavelica, Department of Huancavelica, in the Republic of Peru; approximately 200 km southeast of Lima. A 43-101 Technical Report exists, which refers to a number of vein mineralizations characterized by elevated silver, lead and zinc content with averages of 290 g/t, 65 percent and 7 percent respectively. The Santa Rita, based on the engineering report, has open pit potential with an excess of 1,300,000 tons of mineralization identified.

The Company also has The Hotstone Gold Property. This Property consists of 5 claim blocks (approximately 120 hectares). It is 50 kilometers southeast of Chapleau, Ontario, and 130 km southwest of Timmins, Ontario in the heart of the Swayze Greenstone Belt, an extension of the famous Abitibi Greenstone Belt and the Porcupine and West Porcupine Gold Mining Camps. The Hotstone Gold Property is a drill ready gold prospect.

In January 2012, Coastal Pacific Mining entered into an Option Agreement with Trio Gold on the Hotstone Gold Property. Coastal Pacific, along with D.L. Gibson (the Optionor) and Trio Gold of Calgary, Alberta, reached an arrangement to Option the Hotstone Gold property.  The new Option Agreement supersedes and replaces the Option Agreement from March 29, 2011 between Coastal and D.L. Gibson.

Under the terms of the new agreement dated January 6, 2012, between Coastal, the Optionor and Trio, Trio has the option to earn, upon fulfilling the terms of the Agreement, a 50 percent interest in the Hotstone Gold Property. Coastal and the Optionor will each maintain a 25 percent interest in the Property, upon completion of the Option Agreement. Within the terms of the Option agreement, Trio will commit to $1,300,000 in exploration expenditures on the Property and make cash payments of $200,000 to the Optionor. 

Moreover, the Optionor will be granted a 1 percent Net Smelter Return (NSR) registered to the Hotstone Gold Property. Coastal Pacific Mining and Trio collectively have the option to purchase the Optionor's 25 percent interest for $2,000,000 and the registered 1 percent NSR for a further $1,000,000.

Coastal Pacific Mining Corp. (CPMCF), closed Monday’s session at $0.0086, down 27.73%, on 227,300 volume with 8 trades. The average volume for the last 60 days is 87,607 and the stock's 52-week low/high is $0.001/$0.03.

Interleukin Genetics, Inc. (ILIU)

MicroCap Gems and FeedBlitz reported earlier on Interleukin Genetics, Inc. (ILIU), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Trading on the OTCQB, Interleukin Genetics, Inc. is a genetics-focused personalized health company. They develop and market a line of genetic tests under the Inherent Health® and PST brands®. These products enable individuals to prevent certain chronic conditions and manage their existing health and wellness via genetic-based insights with actionable guidance. Founded in 1986, Interleukin Genetics has their corporate headquarters in Waltham, Massachusetts. The Company operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).

Interleukin Genetics takes advantage of their research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. They market their tests by way of partnerships with health and wellness companies, healthcare professionals and other distribution channels.

The Company's flagship products include their proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists. The PST® Genetic Susceptibility Test is the first and only genetic test that analyzes two interleukin 1 (IL1) genes for variations that identify an individual's predisposition for over-expression of inflammation and risk for periodontal disease.

Their flagship products also include the Inherent Health Weight Management Genetic Test. It identifies the most effective diet and exercise program for an individual based on genetics. The Weight Management Test offers a genetics-based program that will determine whether an individual is likely to benefit more from a low fat, low carbohydrate or balanced calorie reduced diet, and whether an individual is likely to obtain more benefit from normal or more vigorous exercise to most efficiently lose weight.

Interleukin Genetics has research collaborations with Stanford University, University of Sheffield, Tufts University, New York University, Harvard University, the Mayo Clinic, California Pacific Medical Center, Boston University, the University of Arkansas, Tongji Medical College, University of North Carolina, and Yonsei University for the development of their genetic risk assessment tests and other products.

Recently, Interleukin Genetics announced that they would host a conference call and Webcast on Wednesday, November 14, 2012 at 4:30 p.m. ET to discuss their third quarter results. The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics' website at http://www.ilgenetics.com.

Interleukin Genetics, Inc. (ILIU), closed Monday’s session at $0.3499, down 10.28%, on 9,900 volume with 3 trades. The average volume for the last 60 days is 11,332 and the stock's 52-week low/high is $0.17/$0.55.

Alliqua, Inc. (ALQA)

ExclusiveStockAlerts reported today on Alliqua, Inc. (ALQA), WallStreetGrand did earlier, and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Alliqua, Inc. is a biopharmaceutical company focusing on the development, manufacturing and distribution of their proprietary transdermal wound care and drug delivery technologies. The Company's leading technology platform produces hydrogels, a three-dimensional cross-linked network of water-soluble polymers capable of many chemical configurations. Alliqua's shares trade on the OTCQB. The Company has their corporate headquarters in New York City.

The design of Alliqua's core transdermal delivery technology platform is to deliver drugs and other beneficial ingredients through the skin.  Transdermal delivery has multiple advantages over conventional oral and injection delivery. These include the avoidance of hepatic first pass metabolism causing less stress on the liver; its non-invasive nature; improved patient compliance; discontinuation of administration by removal of the system; lower dosage; no dependence on different metabolic rates of individuals; and no interaction with the gastrointestinal system.

Currently, Alliqua markets their new line of 510K FDA approved hydrogel products for wound care under their SilverSeal® brand. The Company can aggressively develop and custom manufacture a broad assortment of hydrogels. This is because of their electron beam production process at their 16,000 square foot GMP manufacturing facility.

They can customize their hydrogels for a variety of transdermal applications to address market opportunities in the treatment of wounds such as diabetic ulcers, and the delivery of a number of drugs or other agents for the pharmaceutical and cosmetic industries. Pharmaceutical companies can increase patient compliance as well as potentially extend the life of valuable drug patents through utilizing Alliqua's drug delivery platform in combination with certain drugs.

The Company's Alliqua Biomedical intends to develop, manufacture and market their own proprietary products, using the existing technology portfolio available to them via the other subsidiaries of Alliqua. They also intend to pursue projects in the fields of active ingredient and transdermal drug delivery, and advanced wound care.

Alliqua's AquaMed Technologies, Inc. manufactures custom hydrogels. Alliqua's HepaLife BioSystems, Inc. is the developer of HepaMate™. This is an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure.

Last month, Alliqua announced the appointment of Mr. James Sapirstein to the position of Chief Executive Officer of Alliqua to lead the Company's strategic growth plan. In connection with Mr. Saperstein's appointment, Mr. Richard Rosenblum will transition from President to Executive Co-Chairman and serve along with David Stefansky as Executive Co-Chairmen.

Alliqua, Inc. (ALQA), closed Monday’s session at $0.058, up 7.41%, on 1,785,788 volume with 69 trades. The average volume for the last 60 days is 167,548 and the stock's 52-week low/high is $0.03/$0.103.

Alpha Minerals, Inc. (AMW.V)

We are highlighting Alpha Minerals, Inc. (AMW.V) today, here at the QualityStocks Daily Newsletter.

Listed on the TSX Venture Exchange, Alpha Minerals, Inc. is a junior mineral exploration company with strategically selected Uranium and Gold properties in North America. Effective November 2, 2012, ESO Uranium became Alpha Minerals. Alpha Minerals has approximately 240,000 acres of prospective Uranium and Gold claims distributed throughout North America. The Company has their headquarters in Vancouver, British Columbia.

Alpha Minerals' Athabasca Basin Properties are Patterson Lake South, Cluff, Hook, and Cree. They total more than 225,000 acres. The Athabasca Basin in Northern Saskatchewan, Canada is the world's most important uranium producing district.

The Company's Mikwam Gold Property is in North Eastern Ontario, Canada. It totals approximately 2,400 acres within the western extension of the Casa Berardi Deformation Zone. Alpha Minerals' Donna Gold Property is in British Columbia, Canada. It totals approximately 5,370 acres. The property is in the Monashee Mountains. The property lies in the headwaters of the famous Kettle River Gold Placer Camp.

Today, Alpha Minerals and their Joint Venture partner Fission Energy Corp. (FIS.V) released additional results from their current core drill program. The 31,039 hectare PLS project is a 50/50 Joint Venture held by Alpha Minerals and Fission Energy. Fission is the Operator.

Since the announcement of the discovery hole PLS12-022 (news release Nov. 5, 2012), two more vertical holes have been completed. These are PLS12-023 located 10 meters grid north of Hole PLS12-022 and Hole PLS12-024 located 10 meters grid west of PLS12-022.

PLS12-023 intersected approximately 13 meters (42.9 feet) of strongly anomalous radioactivity over the core interval between 63.0-76.0 meters downhole with visible uranium mineralization and extensive alteration. PLS12-024 intersected approximately 24 meters (79.2 feet) of strongly anomalous radioactivity over the core interval between 59.0 - 93.0 meters with a 13.0 m wide interval of mineralization which includes intermittent intervals, totaling 2.14m, of off-scale (>9999 cps) radioactivity.

Alpha Minerals, Inc. (AMW.V), closed Monday’s session at $1.36, up 60.00%, on 1,106,991 volume. The stock's 52-week low/high is $0.02/$0.89.

Tix Corp. (TIXC)

SmarTrend Newsletters and Wall Street Resources reported earlier on Tix Corp. (TIXC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Tix Corp. is an entertainment company that provides discount ticketing services. Currently, the Company operates ten discount ticket stores in Las Vegas, Nevada under the Tix4Tonight marquee. They offer up to a 50 percent discount for same-day shows, concerts, attractions and sporting events, as well as reservations for discount dining. Tix lists on the OTC Markets: OTCQX U.S. The Company is based in Studio City, California.

The Company's Tix4Tonight offers more than 75 shows and attractions each day. Availability varies each day. Every show is not offered every day; however, the Company has received tickets for every show on the Las Vegas Strip at one point or another. Their Tix4Dinner offers half price dinner reservations at Las Vegas restaurants. Their Tix4Dinner also offers discounts on buffets and other "all-you-can-eat" style restaurants.

Tix4Tonight obtains their inventory of discount tickets under short-term exclusive and non-exclusive agreements with almost every Las Vegas show along with many attractions and tours. Each discount ticket location also offers discount dinner reservations at a variety of restaurants surrounding the Las Vegas strip and downtown, with dining at specific times on the same day or advance in some cases.

Today, Tix reported results for the third quarter and first nine months ended September 30, 2012. Third quarter 2012 revenues decreased 10 percent to $6.4 million compared with $7.1 million for the same period a year ago. The decline in revenues of $712,000 is due to a general overall decrease in travel to, and consumer spending in Las Vegas. The decline is also due to the closing of three of the Company's bestselling shows for which there has been no comparable replacement; and recent demolition work on the Las Vegas strip requiring Tix to close one of their discount ticket locations at the end of April 2012.

Third quarter 2012 net income was $768,000, or $0.03 per diluted common share. This is compared to a net income of $647,000, or $0.03 per diluted common share, reported for the same period a year ago.

For the first nine months of 2012, revenues decreased 2 percent to $18.4 million compared to $18.8 million for the same period a year ago. For the first nine months of 2012, net income was $568,000, or $0.02 per diluted common share. This is in comparison to a net income of $2.2 million, or $0.09 per diluted common share, reported for the same period a year ago.

Tix Corp. (TIXC), closed Monday’s session at $1.21, down 5.47%, on 9,300 volume with 7 trades. The average volume for the last 60 days is 2,115 and the stock's 52-week low/high is $1.25/$2.05.

Advaxis, Inc. (ADXS)

PennyTrader Publisher, Real Pennies, and FeedBlitz reported earlier on Advaxis, Inc. (ADXS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Advaxis, Inc. is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. A clinical-stage biotechnology company, Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all individuals have to the bacterium, to the cancer itself. Advaxis lists on the OTC Bulletin Board. The Company has their headquarters in Princeton, New Jersey.

In April of this year, Advaxis' lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. ADXS-HPV is undergoing evaluation in four clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neck cancer (University of Liverpool/CRUK UK study, Clinical Trials.gov Identifier NCT0CT01598792).

More than15 distinct constructs are in various stages of development, developed directly by Advaxis and via strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

At the end of October 2012, Advaxis updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV taking place in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy. Dr. Robert Petit, Advaxis, presented the update in an oral presentation on Saturday, October 27, 2012 at the Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting in North Bethesda, Maryland. The Phase 2 trial assesses the safety and efficacy of ADXS-HPV (1x109 cfu) alone, compared to ADXS-HPV plus cisplatin (40 mg/m2, weekly x5). There are 55 patients in each group.

The primary endpoint of the study is overall survival. As of October 22, 2012, landmark survival at 6, 9, 12, and 18 months was 65 percent, 44 percent, 33 percent, and 17 percent respectively. There appears to be no difference in survival between the two groups.

In addition, at the end of October, Advaxis announced that they secured $10 million in equity financing from Magna Group, LLC, through their flagship Equity Enhancement Program, with an additional $1.4 million in financial commitments from a combination of sources.

Advaxis, Inc. (ADXS), closed Monday’s session at $0.0416, up 26.06%, on 3,013,244 volume with 66 trades. The average volume for the last 60 days is 667,707 and the stock's 52-week low/high is $0.034/$0.189.

Dolly Varden Silver Corp. (DV.V)

Streetwise Reports reported previously on Dolly Varden Silver Corp. (DV.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dolly Varden Silver Corp. is a mineral exploration company whose shares trade on the TSX Venture Exchange. The Company focuses on the exploration and development of the Dolly Varden silver project located in northwestern British Columbia (BC). In 1910, the Dolly Varden Mine was discovered by four prospectors of Scandinavian descent. The name 'Dolly Varden' is from a heroine of Dickens' Barnaby Rudge. Dolly Varden Silver has their headquarters in Vancouver, BC.

The Dolly Varden silver project consists of 9,400 hectares. This includes four well-defined high-grade silver deposits; two have seen historic production totaling 20 million ounces. All four deposits have remaining historic silver resources and are in the same geologic setting as the past-producing Eskay Creek deposit.

The Company has two strategies for creating value at the Dolly Varden silver project. One is to confirm and expand the existing historic silver resources with the goal to re-start the historic deposits. The second is to explore a major untested Eskay Creek-type gold and silver rich VMS target at Dolly Varden. The Dolly Varden Mine properties have produced assays of ore as high as 2200 ounces (over 72 kilograms) of silver per ton. The mines have historic production of 20 M oz Ag.

Dolly Varden Silver owns 100 percent of the Dolly Varden Mines historic silver property. This property is best considered an advanced exploration stage property with well-understood targets. Mine restarts will require the discovery of additional silver mineral resources and the confirmation of historic mineral resources that were known at the termination of mining in 1959.

An historic resource estimate completed on the properties in 1986 estimated 5.7 M ounces of silver (proven and probable) and 8.8 M oz of silver (possible) (Estimated by Derry Michener Booth and Wahl in 1986).  A qualified person has not done sufficient work to classify this historical estimate as current mineral reserves or mineral resources (as those terms are defined in NI 43-101) and Dolly Varden Silver is not treating this historical estimate as current mineral reserves or current mineral resources.

The objective of the Company's exploration work is to confirm and reclassify the historic resources as current mineral resources, and to expand the resource to a target of 40 to 50 million ounces of Silver. If successful, the necessary economic and technical studies would be undertaken to determine if the deposit(s) could become a viable mining operation.

Dolly Varden Silver Corp. (DV.V), closed Monday’s session at $0.205, down 2.38%, on 51,299 volume. The stock's 52-week low/high is $0.12/$0.47.


The QualityStocks
Company Corner



The QualityStocks Daily Newsletter would like to spotlight VIASPACE, Inc. (VSPC). Today, VIASPACE, Inc. closed trading at $0.013, off by 7.80%, on 1,352,098 volume with 27 trades. The stock’s average daily volume over the past 60 days is 1,485,116, and its 52-week low/high is $0.0013/$0.015.

VIASPACE, Inc. (VSPC) is focused on growing renewable Giant King™ Grass as a low-carbon fuel for clean electricity generation and environmentally friendly energy pellets, as well as a feedstock for bio-methane production, green cellulosic biofuels, biochemical, and biomaterials. A high-yield, low-cost feedstock, Giant King Grass meets the cost targets of green energy applications while maintaining a carbon neutral profile.

The highest yielding biomass crop in the world, Giant King Grass can grow in a variety of soil conditions and does not compete with food crops. Once Giant King Grass is established, it can be harvested at 3-5 feet tall every 45 to 60 days or at 14 feet tall twice a year. This incredibly high rate of growth provides a continual supply of biomass year-round, enabling strategically located power plants to operate 24 hours a day regardless of the current season.

VIASPACE provides Giant King™ Grass seedlings and technical expertise to qualified projects. The company also plans to serve as a project developer or co-developer for power plant or pellet mill projects, together with local partners that have land and require electricity, heat, pellets, biogas, or biofuels. VIASPACE and its partners are capable of delivering an integrated Giant King Grass plantation and biomass power plant project in just 24 months.

The excellent energy characteristics of Giant King Grass and its ability to be harvested multiple times each year enable and energy output yield that is much higher than other crops . This superior feedstock offers material productivity benefits at remarkable costs for energy production, biofuels, and biomaterials. Giant King Grass is currently being grown in the United States, Virgin Islands, China, and other areas. Disclaimer

VIASPACE, Inc. Company Blog

VIASPACE, Inc. News:

VIASPACE CEO Presents at Asian Development Bank Renewable Energy Conference and Meets Customers in Myanmar

Board Chairman Interviews With TheStockRadio Program Regarding the Future of VIASPACE

USDA Approved Giant King Grass Growing in California

GlobalWise Investments, Inc. (GWIV)

The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.40, up 14.29%, on 2,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 6,299, and its 52-week low/high is $0.35/$1.87.

GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.

GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.

GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer

GlobalWise Investments Company Blog

GlobalWise Investments News:

GlobalWise Teams Up With MWA Intelligence to Participate in Two Imaging Channel Conferences

GlobalWise Announces New Channel Partnership With Level Seven

GlobalWise Announces Appointment of Kendall D. Gill to Chief Financial Officer Position

TNI BioTech, Inc. (TNIB)

The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $8.15, up 8.96%, on 47,111 volume with 99 trades. The stock’s average daily volume over the past 60 days is 45,178, and its 52-week low/high is $0.72/$10.01.

TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.

The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.

The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer

TNI BioTech, Inc. Company Blog

TNI BioTech, Inc. News:

TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer

TNI BioTech Signs Agreement With Government of Malawi to Open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital

Skinny Nutritional Corp. (SKNY)

The QualityStocks Daily Newsletter would like to spotlight Skinny Nutritional Corp. (SKNY). Today, Skinny Nutritional Corp. closed trading at $0.0019, up 5.56%, on 1,42,500 volume with 21 trades. The stock’s average daily volume over the past 60 days is 1,238,139, and its 52-week low/high is $0.0015/$0.03.

Skinny Nutritional Corp. (SKNY) has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water's proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water.

The company has constructed a network of approximately 50 domestic distributors (with three more internationally), placing product on shelves approximately 15k stores across the United States. Derived from the natural flavors contained in fruits, Skinny Water represents a fortified, extremely low-impact, great-tasting array of beverages that provide a concentrated punch of the nutrients essential for a healthier lifestyle.

The company's strong emphasis on health, fitness, and community has served marketing initiatives very well. The new age beverage segment has seen increasing momentum in recent years, with just about every beverage company getting into the game, but none of them has the kind of no-nonsense product composition behind Skinny Water, something that appeals directly to the majority of the core consumer market.

Skinny Nutritional continues to build value around the Skinny Water brand, and today has numerous trademarks in the healthy beverage and snack food categories. As consumers migrate away from sugar based beverages and empty calories, Skinny Water is ideally positioned to benefit from positive market trends as management focuses on delivering exceptional value to shareholders. Disclaimer

Skinny Nutritional Corp. Blog

Skinny Nutritional Corp. News:

Skinny Nutritional Corp. Provides Update on Discussions With Trim Capital

Skinny Nutritional Corp. to Change the Way You Think About Your Water With the Introduction of Skinny Water pH+

A&P's 275 Stores Continue Skinny Water's Mid-Atlantic Penetration

VIASPACE, Inc. (VSPC) Video Chart for Monday, November 12, 2012

VSPC made a strong move recently to make new 52-week highs after a breakout from a flag pattern. The chart moved back upward on Friday after a quick consolidation. It’s on radar to continue the momentum to test resistance at $0.015 and possibly make another new high.

To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts

TNI BioTech, Inc. (TNIB) Helps Lead the Way to a New Africa

When TNI BioTech recently signed an agreement to open an Oncology & Infectious Disease Clinic at Queen Elizabeth Central Hospital in Malawi, in southwestern Africa, it reflected an ongoing change in the attitude of the industrialized world toward Africa. Once largely ignored because of its troubled political history and lack of infrastructure and technology, Africa is suddenly rising on the world’s economic radar. The second largest land mass on the globe, with the second largest population of any continent, Africa has been seeing rapid economic growth, and has been compared to Asia in its potential.

In a Seeking Alpha article, “The Case For Investing In Africa”, Peter Thoms points out that Africa’s recent economic growth is just one of the reasons that investors should take a long look at the continent, and cites a number of other attractive factors:

• Africa’s immense natural wealth
• Africa’s youthful demographics
• Africa’s growing embrace of technology
• Africa’s developing integration with the global economy

Africa is made up of many diverse countries, each with its own challenges, but challenges that, for the above reasons, are now being viewed as early-game opportunities.

In the case of TNI BioTech’s agreement with Malawi to open a clinic, the new clinic will not only be important to the people of Malawi, through greatly improved cancer treatment, but will also allow TNIB, in conjunction with GB Oncology & Imaging Group, to study the interaction between infections and cancer by promoting cutting-edge research aimed at pathophysiology, prevention, diagnosis, and treatment of infection-related cancers in Africa. In particular, it is believed that IRT-103, TNIB’s active immunotherapy that works by activating a patient’s immune system against HIV/AIDS and tumor cells, can be demonstrated to be capable of saving millions of lives.

In short, as Africa rises, so can the companies and individuals with the foresight to invest early in this massive and rich part of the world that is no longer being called the dark continent.

For additional information, visit www.TNIBiotech.com

Cardium Therapeutics, Inc. (CXM) Follows the Western Lifestyle

For well over a hundred years, industrialized nations have continued to export a wide range of manufactured goods and associated technologies to developing countries throughout the world. More than altruism, it was viewed as an immediate economic opportunity, but also as a way of gradually lifting less developed countries into the modern world where, it was hoped, they would become even better customers. In parallel with this was the export of Western ideas: democracy, capitalism, the value of abundance, and the value of consumption.

America has played a leading role in all of this, with some unintended consequences. Because, along with all of the tractors and electronics, along with all of the democracy and marketplace economics, America has successfully exported the western lifestyle, which, as we now know, has some challenges that many people didn’t think much about a hundred or even fifty years ago; things like obesity, heart disease, and diabetes, diseases that are now epidemic in the U.S.

The U.S. and industrialized countries have now had some experience with the consequences of a western lifestyle, and so they have a good idea of what to expect as developing countries start to go down the same path. As a result, they recognize developing markets in these developing countries. For example, it is now estimated that fully 80 percent of future increases in coronary heart disease will occur outside the U.S.

For Cardium Therapeutics, and its lead product Generx, the spread of western ailments to developing parts of the world means an increasing need for what the company and Generx can offer. Generx is a DNA-based growth factor that is designed to actually stimulate the growth of new blood vessels around the heart. In the U.S., the need for increased heart blood flow is often met with expensive and technically complicated surgery, together with long-term followup, the kind of things that are often not readily available in developing parts of the world. But Generx involves none of that, making it a strong candidate for millions of people who could otherwise go untreated.

For additional information, visit www.CardiumTHX.com

VistaGen Therapeutics, Inc. (VSTA) Taps the Turnaround

The idea of a turnaround is often associated with dysfunctional companies being purchased by outsiders or otherwise given new management, and then being transformed with a change in product, structure, or philosophy, providing a fresh and profitable direction for what had been a losing asset. If coming from the outside, the process can be extremely lucrative, allowing a purchase or major stake at bargain basement prices, and then rapidly growing that investment through the application of proven principles. Individuals and companies who have taught themselves how to identify and resolve corporate weaknesses stand to profit handsomely once they have the resources to get in on the action.

VistaGen Therapeutics seeks to apply the turnaround concept in a creative new way that could end up turning millions and perhaps billions of dollars in lost pharmaceutical development into positive revenue. Using their proprietary stem cell technology, VistaGen has been able to develop a revolutionary bioassay platform that allows drug developers to accurately test for things like heart toxicity right in the laboratory, prior to lengthy clinical testing and well before going to the huge expense and risk of taking a drug to market. Such early in-lab testing allows developers to carefully guide the initial formulation of drug candidates, providing an effective new way to develop drugs and even rescue previously shelved drug candidates.

VistaGen’s stated goal is to use their advanced stem cell technology to build a diverse drug pipeline consisting of new, proprietary small molecule “drug rescue variants” which are as effective as once promising drug candidates but without the heart or liver toxicity that caused them to be put on the shelf. They are, in effect, looking to identify and then turn around approaches that had been considered largely lost. They believe each lead drug rescue variant will have the potential to be a new drug candidate in which they plan to have economic participation rights (up front and development milestone payments and royalties on commercial sales).

Considering that it can easily take on average investment of $800 million to $1.7 billion, plus 12 to 15 years, before a new drug candidate reaches the market, all of which can be lost due to unexpected and often late-discovered heart or liver toxicity problems, the value of a novel in vitro technology, a Clinical Trial in a Test Tube™, that can help rescue part or the entirety of that large investment is clear.

For additional information, visit www.VistaGen.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Street Penny Stocks


Whisper from Wall Street



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors

The QualityStocks By The Numbers Report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251